World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
53
Citations
12732
World Ranking
3953
National Ranking
349

Syd Johnson publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Syd Johnson sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 104 publications — 4th percentile

4% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Syd Johnson D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Syd Johnson sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 53 D-Index — 20th percentile

20% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Syd Johnson is affiliated with AstraZeneca in the United Kingdom. Their research primarily focuses on medicine, with a notable emphasis on immunology and microbiology.

The scientist's work encompasses several subfields, including infectious diseases, immunology, virology, epidemiology, and public health, environmental and occupational health.

Key topics addressed in their research include:

  • HIV Research and Treatment
  • HIV/AIDS drug development and treatment
  • Immune Cell Function and Interaction
  • Mosquito-borne diseases and control
  • Viral Infections and Vectors
  • Viral Infections and Outbreaks Research
  • Immunotherapy and Immune Responses

Johnson has contributed to research articles published in venues such as UNC Libraries and Human Immunology. Notable recent publications include:

  • "Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells," 2020, UNC Libraries
  • "Development of a Highly Protective Combination Monoclonal Antibody Therapy against Chikungunya Virus," 2020, UNC Libraries
  • "Uncovering new potentials: High resolution deceased donor human leukocyte antigen typing in less than 4 hours," 2024, Human Immunology

Johnson frequently collaborates with other researchers, including Julia Sung, Joy Pickeral, Liqin Liu, Sherry Stanfield-Oakley, and Chia-Ying K. Lam.

Best Publications

  • Development of a Humanized Monoclonal Antibody (MEDI-493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial Virus

    Syd Johnson;Cynthia Oliver;Gregory A. Prince;Val G. Hemming

  • Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus

    Theodore Oliphant;Michael Engle;Grant E Nybakken;Chris Doane

  • Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial.

    Nicole Sherry;William Hagopian;Johnny Ludvigsson;Sunil M Jain

  • Use of a Whole Genome Approach To Identify Vaccine Molecules Affording Protection against Streptococcus pneumoniae Infection

    Theresa M. Wizemann;Jon H. Heinrichs;John E. Adamou;Alice L. Erwin

  • Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

    Herren Wu;David S. Pfarr;Syd Johnson;Yambasu A. Brewah

  • Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγ receptors

    Jeffrey B. Stavenhagen;Sergey Gorlatov;Nadine Tuaillon;Christopher T. Rankin

  • Lethal Antibody Enhancement of Dengue Disease in Mice Is Prevented by Fc Modification

    Scott J. Balsitis;Katherine L. Williams;Ruben Lachica;Diana Flores

  • Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma

    Paul A. Moore;Wenjun Zhang;G. Jonah Rainey;Steve Burke

  • In Vivo Tumor Targeting of a Recombinant Single-Chain Antigen-Binding Protein

    David Colcher;Robert Bird;Mario Roselli;Karl D. Hardman

  • Structural basis of West Nile virus neutralization by a therapeutic antibody

    Grant E. Nybakken;Theodore Oliphant;Syd Johnson;Stephen Burke

  • Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity

    Deryk Loo;Ralph F. Alderson;Francine Z. Chen;Ling Huang

  • Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis.

    John E. Adamou;Jon H. Heinrichs;Alice L. Erwin;William Walsh

  • Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion.

    Syd Johnson;Stephen Burke;Ling Huang;Sergey Gorlatov

  • Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants.

    Whitney E. Purtha;Thomas F. Tedder;Syd Johnson;Deepta Bhattacharya

  • Development of a Highly Protective Combination Monoclonal Antibody Therapy against Chikungunya Virus

    Pankaj Pal;Kimberly A. Dowd;James D. Brien;Melissa A. Edeling

  • Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties

    Jeffrey L Nordstrom;Sergey Gorlatov;Wenjun Zhang;Yinhua Yang

  • Monoclonal antibodies capable of discriminating the human inhibitory Fcγ-receptor IIB (CD32B) from the activating Fcγ-receptor IIA (CD32A): biochemical, biological and functional characterization

    Maria-Concetta Veri;Sergey Gorlatov;Hua Li;Steve Burke

  • The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1

    Bimmi Shrestha;James D. Brien;Soila Sukupolvi-Petty;S. Kyle Austin

  • Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.

    William Hagopian;Robert J. Ferry;Nicole Sherry;David Carlin

  • Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.

    Soila Sukupolvi-Petty;S. Kyle Austin;Michael Engle;James D. Brien

Frequent Co-Authors

Ezio Bonvini
Ezio Bonvini Center for Biologics Evaluation and Research
Scott Koenig
Scott Koenig MacroGenics (United States)
Paul A. Moore
Paul A. Moore MacroGenics (United States)
Michael S. Diamond
Michael S. Diamond Washington University in St. Louis
Daved H. Fremont
Daved H. Fremont Washington University in St. Louis
Theodore C. Pierson
Theodore C. Pierson National Institute of Allergy and Infectious Diseases
Jennifer R. Brown
Jennifer R. Brown Harvard University
Eva Harris
Eva Harris University of California, Berkeley
John D. Morrey
John D. Morrey Utah State University
Giorgio Inghirami
Giorgio Inghirami Cornell University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to numerous healthcare and research careers, but many students also consider complementary pathways in nursing and mental health. For those interested in a faster entry into clinical roles, exploring accelerated nursing programs near me can be a smart move. These programs allow students with prior degrees to quickly transition into nursing careers.

If you are looking for foundational nursing credentials, the best easiest lpn programs to get into provide accessible training options. Licensed Practical Nurses often work closely with immunologists in clinical environments, supporting patient care focused on immune health.

For those aiming for advanced practice roles, considering nurse practitioner programs with easy admission can facilitate career progression without extensive barriers to entry. These programs blend clinical training with leadership skills essential in immunology-related healthcare settings.

Finally, specialized fields like psychiatric care intersect with immunology, particularly in neuroimmunology. Students can explore best online psychiatric mental health nurse practitioner programs that offer excellent clinical placements, preparing graduates for impactful roles in mental and immune health integration.

Best Scientists Citing Syd Johnson

Trending Scientists